Drug Trial Radar · NCT04634409
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Last checked: Nov 19, 2026Latest source record: Jul 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,755
Actual
Start
Oct 29, 2020
Primary completion
Jul 27, 2021
Study completion Oct 18, 2021
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- AbCellera Biologics Inc.; Shanghai Junshi Bioscience Co., Ltd.; GlaxoSmithKline; Vir Biotechnology, Inc.
- First posted
- Nov 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone.
Conditions
- COVID-19
Interventions
BamlanivimabDrug
Administered IV.
EtesevimabDrug
Administered IV.
PlaceboDrug
Administered IV.
VIR-7831Drug
Administered IV.
BebtelovimabDrug
Administered IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Greater Than 5.27Time frame: Day 7
- Treatment 7-8, Amendments (C-e): Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27Time frame: Day 7
- Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27Time frame: Day 7
Locations
141 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
The Institute for Liver Health
Mesa, Arizona
Perseverance Research Center
Scottsdale, Arizona
CRI of Arizona, LLC
Sun City West, Arizona
Fiel Family and Sports Medicine PC
Tempe, Arizona
The Institute for Liver Health
Tucson, Arizona
KLR Business Group, Inc. dba Arkansas Clinical Research
Little Rock, Arkansas
Applied Rsch Ctr - Arkansas Inc.
Little Rock, Arkansas
Smart Cures Clin Research
Anaheim, California
Hope Clinical Research
Canoga Park, California
VCT-Covina
Covina, California
Neighborhood Healthcare
Escondido, California
Chemidox Clinical Trials
Lancaster, California
Ark Clinical Research
Long Beach, California
Long Beach Clinical Trials LLC
Long Beach, California
Cedars Sinai Medical Center
Los Angeles, California
Central Valley Research, LLC
Modesto, California
Inland Empire Liver Foundation
Rialto, California
Sutter Institute For Medical Research
Sacramento, California
Wolverine Clinical Trials, LLC
Santa Ana, California
St. Joe Heritage HC-Santa Rosa
Santa Rosa, California
Stanford University Hospital
Stanford, California
Mazur, Statner, Dutta, Nathan
Thousand Oaks, California
South Bay Clinical Research Institute
Torrance, California
Infect Disease Doctors Med Grp
Walnut Creek, California
Allianz Research Institute
Westminster, California
Future Innovative Treatments LLC
Colorado Springs, Colorado
Georgetown Univ Sch of Med
Washington D.C., District of Columbia
Synergy Healthcare LLC
Bradenton, Florida
Holy Cross Hospital Inc.
Fort Lauderdale, Florida
I R & Health Center, Inc.
Hialeah, Florida
Encore Medical Research
Hollywood, Florida
Elixia CRC
Hollywood, Florida
Lakeland Regional Medical Center
Lakeland, Florida
Hope Clinical Trials, Inc.
Miami, Florida
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida
Bio-Medical Research, LLC
Miami, Florida
Clinical Site Partners, LLC d/b/a CSP Miami
Miami, Florida
Panax Clinical Research
Miami Lakes, Florida
Testing Matters Lab
Sunrise, Florida
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.